Prospective clinical study of once monthly ibandronate in the treatment of osteoporosis and prevention of fractures in postmenopausal women: Orpheum study by Bumbaširević Marko et al.
790
Srp Arh Celok Lek. 2011 Nov-Dec;139(11-12):790-794  DOI: 10.2298/SARH1112790B 
ОРИГИНАЛНИ РАД / ORIGINAL ARTICLE  UDC: 616.71-007.233-08
Correspondence to:
Aleksandar LEŠIĆ
Clinic for Orthopaedic Surgery 
and Traumatology
Clinical Centre of Serbia
Dr Koste Todorovića 26
11000 Belgrade
Serbia
alesic@sbb.rs
Prospective Clinical Study of Once Monthly 
Ibandronate in the Treatment of Osteoporosis and 
Prevention of Fractures in Postmenopausal Women: 
ORPHEUM Study
Marko Bumbaširević1,2, Aleksandar Lešić1,2, Ljiljana Denić-Marković3, Kristina Živković1,2; and 
ORPHEUM Study Group
1Clinic for Orthopaedic Surgery and Traumatology, Clinical Centre of Serbia, Belgrade, Serbia;
2School of Medicine, University of Belgrade, Belgrade, Serbia;
3Institute for Epidemiology, School of Medicine, University of Belgrade, Belgrade, Serbia
INTRODUCTION
Osteoporosis is defined as a systemic disorder 
with reduced body mass and microarchitec-
tural defects of the bone tissue. It is a serious 
problem, since about 50% of women over the 
age of 50 suffer at least one osteoporotic frac-
ture [1]. Increased fragility as well as reduced 
bone resistance predispose to the increased 
risk of fractures. The possibility of measuring 
bone mineral density (BMD) enables patients 
at increased risk to be identified even before 
the occurrence of fracture, thus treatment can 
be initiated on time [2]. Dual energy X-ray 
absorptiometry (DXA) for the assessment of 
bone mineralization is the gold standard for 
establishing the diagnosis of osteoporosis. A 
multidisciplinary approach is the key in both 
diagnosis and treatment of this condition. Non-
pharmacological treatment methods, including 
food supplements (vitamin D and calcium) and 
a change in lifestyle, complement the pharma-
cological treatment of osteoporosis and miti-
gation of risk factors. Among the number of 
medicaments available for therapy, bisphos-
phonates are recognized as highly important.
Bisphosphonates are an antiresorptive class 
of drugs efficient in both prevention and treat-
ment of osteoporosis [3]. They interfere in the 
normal resorptive metabolic pathway of osteo-
clasts [4]. Randomized clinical studies have 
shown that oral administration of bisphos-
phonates increases bone mineral density, thus 
decreasing the risk of fractures in women with 
postmenopausal osteoporosis [5, 6]. A daily 
dose schedule of oral bisphosphonates has been 
shown to lessen the risk of both vertebral and 
non-vertebral fractures. However, newer dosing 
schedules (once a week, once a month and once 
in three months) have also been beneficial and 
they are simpler to use than daily administra-
tion [5-8].
Oral ibandronate was the first oral bisphos-
phonate that can be used once a month for treat-
ing osteoporosis in postmenopausal women [9]. 
Applied in the dose of 150 mg once a month it is 
equally efficient at increasing BMD and reduc-
ing bone remodeling markers in older women 
with osteoporosis in whom tolerance appears 
to be better than with once a day administra-
tion [9].
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OBJECTIVE
The purpose of this study was to evaluate the efficiency, 
safety and compliance with ibandronate treatment over a 
6-month period in reducing the risk of subsequent fracture 
in women with postmenopausal osteoporosis.
METHODS
Our multicenter, prospective, observational study was 
conducted from June 2008 to June 2009. Thirteen centres 
participated. The subjects were women only. The inclusion 
criteria comprised reduced BMD index (osteoporosis or 
osteopenia), age (older than 45 years), menopause and risk 
factors for fractures. All patients gave their informed consent 
for participation in the study. Each subject filled in a ques-
tionnaire including data on demographic features, repro-
ductive status, physical activities and main risk factors for 
osteoporosis (fractures in adulthood, low body mass, smok-
ing, alcohol consumption, use of oral corticosteroids for 
three or more months and rheumatoid arthritis). Physical 
activity was defined as low if the subject walked less than 1 
hour out of home daily; moderate – more than 1 hour and 
significant if the subject exercised at least three times a week. 
Other accompanying diseases were also taken into account. 
A part of the questionnaire covered the mode of establish-
ing the diagnosis; DXA, and or skeletal X-ray, profile of the 
specialist making the diagnosis (orthopaedic surgeon, endo-
crinologist, physiatrist or primary care physician). The ques-
tionnaire also included information on previous treatment 
of osteoporosis and BMD values, as well as T-score, specific 
for the location where they were obtained, up to 3 months 
before the ibandronate treatment was started.
In the first part of the study the subjects received iban-
dronate 150 mg tablets once a month for 6 months. After 6 
months of ibandronate treatment, the patients underwent 
clinical follow-up examination in order to detect any spon-
taneous fractures and the occurrence of adverse effects of 
the drug. Follow-up DXA was not performed.
Descriptive statistics (means, standard deviation, 
proportions) was used to analyse the data, while the chi-
square test was used to identify significance of differences 
among some of the variables.
RESULTS
Population description
The study comprised 184 women who were treated in 
healthcare institutions in Serbia due to a history of fractures 
caused by little or no force or osteoporosis. The young-
est patient was 46 and the oldest 89 years old (mean age 
66.2±9.4 years). All women were postmenopausal and only 
six (3.3%) received hormone substitution therapy. The 
average duration from the last menses was 18.5±9.2 years.
Education-wise, the largest number (44.0%) had a 
secondary school diploma, followed by 21.7% with a 
college/university degree and 27.7% with elementary 
education, while 6.5% had no education whatsoever.
Diagnosis of the disease
In 74 (40.2%) subjects the disease was clinically manifested 
over five preceding years. No DXA or X-ray was made in 29 
(15.8%) women before our study. A DXA scan was made 
in 85 (46.2%) subjects (40% DXA of the spine, 28% hip but 
for 32% data on the site were not specified).
In addition to DXA, 32 patients were X-rayed. As 85 
more patients were X-rayed this technique was used for 
diagnosis in a total of 117 (63.3%) patients.
The mean T-score value at the beginning of the study 
was -3.1±0.84 in 160 (87%) patients substantiating the diag-
nosis of osteoporosis, while osteopenia was diagnosed in 
24 (13%) patients. In 92.1% cases the diagnosis was estab-
lished by an orthopaedic surgeon. Table 1 shows the history 
of compressive fractures and spontaneous non-vertebral 
fractures in our subjects. All compression vertebral frac-
tures and all histories of incident fractures were recorded 
in patients with osteoporosis. Out of 100 patients with a 
spontaneous non-vertebral fracture, 38% had a hip frac-
ture, 34% a lower arm-wrist fracture, 10% an upper arm 
fracture and 18% had a fracture at some other location.
Risk factors for osteoporosis
Almost all our patients (96.2%) had some of the main risk 
factors for the development of osteoporosis. On average, 
each had nearly two factors (1.6±0.8). Only three patients 
(1.6%) had the maximum number of four risk factors. A 
history of osteoporotic fractures was much more common 
in patients with three or four risk factors (χ2=18.5; df=4; 
p=0.001) (Table 2).
Association of the history of fractures with the pres-
ence of risk factors is presented in Table 3. Fractures were 
more common (p=0.001) in women with a family history of 
fractures, as well as in women receiving oral corticosteroid 
treatment for over 3 months (p=0.02). The level of exercise 
was low in 74 (40.2%) subjects. Only a very low percentage 
(8.2%) of patients exercised actively or pursued any physi-
Table 1. Type of fracture in patients with osteoporosis and osteopenia
Type of fracture
Number of patients
Osteoporosis Osteopenia Total
Compressive 
vertebral fractures 
only
44 (27.5%) 0 (0.0%) 44 (23.9%)
Spontaneous 
nonvertebral 
fracture only
75 (46.9%) 16 (66.7%) 91 (49.4%)
Associated 
compressive 
vertebral fractures 
and spontaneous 
nonvertebral 
fracture
9 (5.6%) 0 (0.0%) 9 (4.9%)
No fractures 32 (20.0%) 8 (33.3%) 40 (21.7%)
Total 160 (87.0%) 24 (13.0%) 184 (100.0%)792
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cal activity at least three times a week. There was no signif-
icant difference in the occurrence of fractures in patients 
with a low level of physical activity and those that actively 
exercised. Moreover, no significant difference was noted 
when they were compared in terms of smoking status, alco-
hol consumption, low body mass or presence of rheuma-
toid arthritis.
Previous treatment of osteoporosis
Before joining the study, 48 (26.1%) women received 
calcium for the treatment of osteoporosis, 36 (19.6%) vita-
min D, 10 (5.4%) daily bisphosphonates, six (3.3%) weekly 
bisphosphonates, and 10 (5.4%) intravenous bisphospho-
nates.
Bisphosphonate monthly treatment and its effects
Most of the patients (95.8%) received monthly bisphos-
phonates over a 6-month period. Forty-two experienced 61 
adverse events during the study. In 39 cases (63.9%) asso-
ciation of the event and the administered drug could be 
established. Among these only two (3.3%) adverse events 
were classified as serious. The association and the sever-
ity of adverse events in patients receiving bisphospho-
nate monthly with the treatment are presented in Table 
4. Nausea was the most common symptom reported in 
18 (9.8%) patients, followed by vomiting in 6 (3.3%) and 
diarrhoea in four (2.2%) subjects.
During the treatment period, spontaneous fractures 
occurred in 13 (7.1%) patients. Most commonly it was a 
hip fracture (38.5%) or a vertebral fracture (30.8%). In most 
cases the patients stated that they felt well after the treat-
ment (22.3%) or better (20.2%), that the pain was relieved 
(7.6%) and that their mobility was improved (5.4%). Only 
10.9% recorded no change and 7.6% complained of persis-
tent pain. Out of 159 subjects asked whether they wished 
to continue the treatment 91.2% answered affirmatively.
DISCUSSION
The ORPHEUM study was conducted in order to investi-
gate the efficacy, adverse effects and compliance of iban-
dronate treatment in women with reduced BMD index 
in everyday clinical practice. All women included in the 
study were postmenopausal, of average age over 65 years. 
The majority of them had secondary or university educa-
tion (65.7%).
At the beginning of the study most patients had osteo-
porosis diagnosed by an orthopaedic surgeon, which may 
suggest insufficient involvement of doctors in primary 
health care. In the light of serious and severe consequences 
of this chronic disease, such as hip and vertebral fractures 
associated with increased mortality, it is of utmost impor-
tance for osteoporosis to be diagnosed promptly and treat-
ment initiated by a primary care physician (GP or a family 
doctor) [10]. In over 80% of the patients DXA of the spine 
or hip, or X-ray examination substantiated the diagnosis, 
where it had been established on time and precisely. As 
many as 23.9% patients had a history of compressive verte-
bral fracture and osteoporosis was diagnosed in all. Most of 
the previous spontaneous nonvertebral fractures were hip 
fractures. In a four-year follow-up study of 6,500 women 
over 55 years of age, Cauley et al. [11] showed that the rela-
tive risk of a fatal outcome after such a fracture was 2.15. 
The highest mortality was recorded in women with hip 
and vertebral fractures. It has been estimated that women 
aged 50 years or more have a 16% risk of having a hip frac-
ture during their lifetime, 15% suffer a distal radial frac-
ture and 32% a vertebral fracture [12]. Therefore, effective 
prevention of fractures in women with osteoporosis may 
reduce morbidity and mortality.
In addition to the menopause, the most important risk 
factors for osteoporosis include the occurrence of fractures 
in adulthood (46.7%) and a low level of exercise/physical 
activity (40.2%). A history of osteoporotic fractures was 
much more common in patients with three or four risk 
factors, those with a family history of fractures and those 
Table 2. Number of pretreatment fractures in relation to the number 
of risk factors
Risk factors for 
osteoporosis
Pretreatment fractures
Total
No Yes
0 3 (2.2%) 4 (8.2%) 7 (3.8%)
1 72 (53.3%) 11 (22.4%) 83 (45.1%)
2  44 (32.6%) 20 (40.8%) 64 (34.8%)
3 15 (11.1%) 12 (24.5%) 27 (14.7%)
4 1 (0.7%) 2 (4.1%) 3 (1.6%)
Total 135 (73.4%) 49 (26.6%) 184 (100.0%)
Table 4. Adverse events in our patients on once a month oral treatment 
in relation to the duration of treatment
Duration of 
treatment 
(months)
Number of patients
Adverse 
events
Association of 
adverse events 
with study drug
Severe 
adverse 
event
1 17 (9.2%) 12 (70.6%) -
2 11 (6.0%) 7 (63.6%) 1 (9.1%)
3 9 (4.9%) 6 (66.7%) -
4 10 (5.4%) 4 (40.0%) -
5 8 (4.3%) 4 (50.0%) 1 (12.5%)
6 6 (3.3%) 6 (100.0%) -
Table 3. Risk factors in patients with osteoporosis
Risk factor
Number of 
patients 
with history 
of fractures
Number of 
fractures p
Low level of physical 
activity 51 (37.8%) 23 (46.9%) 0.26
Fractures in adulthood 52 (39.3%) 33 (67.3%) 0.001
Low body mass (<58 kg) 34 (25.2%) 14 (28.6%) 0.70
Smoking 40 (29.6%) 20 (40.8%) 0.16
Alcohol 5 (3.7%) 3 (6.1%) 0.44
Use of oral corticosteroids 
>3 months 10 (7.4%) 10 (20.4%) 0.03
Rheumatoid arthritis 7 (5.2%) 6 (12.2%) 0.11
Family history of fractures 
in the elderly 60 (44.4%) 9 (18.4%) 0.001793
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using corticosteroids for over 3 months. Contrary to recent 
findings of Vujasinović-Stupar et al. [13] and Perez et al. 
[14], who reported a significant number of patients without 
risk factors for osteoporosis (29.5%), in our study almost 
all women had at least one of the eight major risk factors. 
This can be explained by the lower number of subjects in 
our investigation and their postmenopausal age as an eligi-
bility criterion for enrolment. In this study smoking, alco-
hol consumption, low body weight and rheumatoid arthri-
tis did not contribute to a higher incidence of history of 
osteoporotic fractures.
Before enrolment, the majority of our patients received 
dietary vitamin D and calcium supplements, while only 
14.1% patients received bisphosphonates daily, weekly or 
intravenously.
Most of our patients (95.8%) received bisphosphonate 
treatment for all six months of the study, as planned in the 
design, indicating very satisfactory compliance. Compliance 
was greater than during the weekly bisphosphonate adminis-
tration regime, suggesting improvement with a less frequent 
dosage schedule [15]. During the treatment the occurrence 
of serious adverse events was very rare (3.3%) and in no case 
was discontinuation of treatment required. In another study 
that lasted a year, the percentage of our patients with adverse 
events was higher (10.5%) [13].The most common of these 
involved the gastrointestinal tract, including nausea, vomit-
ing and diarrhoea, but they were tolerated well. Favourable 
tolerance of the monthly dosing schedule can be explained 
by its lower potential to induce irritation of the oesophageal 
mucosa [15]. A falling trend was noted in the incidence of 
adverse events as the study progressed; from 9.2% in the first 
month of drug administration to 3.3% in the sixth month. 
The percentage of adverse events was expected to fall further 
with continuation of the treatment.
Only 7% of our patients suffered a spontaneous fracture 
during the 6-month treatment. The fracture incidence in 
a recently conducted study (VIBE) was under 2% over a 
12-month period [5]. It should be pointed out that women 
over the age of 65 accounted for a substantial share of our 
sample, and they all had a large number of associated risk 
factors for fractures.
Over 80% of our patients confirmed loss of pain, 
improved mobility and an overall sense of improvement 
after the treatment. Probably because of such improvement, 
over 90% of our subjects stated that they would continue 
the treatment.
CONCLUSION
Ibadronate treatment once a month for 6 months was 
safe, tolerated well and without serious adverse events that 
would require discontinuation. Also, the risk of subsequent 
fractures in the treated postmenopausal women was rela-
tively low.
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КРА ТАК  СА ДР ЖАЈ
Увод Осте  о  по  ро  за је озби  љан про  блем, јер око 50% же-
на  ста ри јих  од  50  го ди на  има  нај ма ње  је дан  осте о по ро тич-
ни пре  лом.
Циљ ра  да Циљ ра  да био је да се про  це  не ефи  ка  сност, си-
гур ност  и  ком пли јан са  ле че ња  ибан дро на том  то ком  шест 
м е  с е  ц и ,   т е   у т в р  д и   с м а  њ е  њ е   р и  з и  к а   н а  с т а н  к а   к о н  с е  к у  т и в -
них  пре ло ма  код  же на  у  пост ме но па у зи.
М е  т о  д е   р а  д а   Мул ти цен трич на,  про спек тив на,  оп сер ва ци-
о на  сту ди ја  из ве де на  је  то ком  јед не  го ди не  у  13  ме ди цин-
с к и х   ц е н  т а  р а   у   С р  б и  ј и .   У   п р  в о ј   ф а  з и   с т у д и  ј е   и с  п и  т а  н и  ц е   с у  
при ма ле  150  mg  ибан дро на та  (та бле те)  јед ном  ме сеч но  то-
ком шест ме  се  ци. У дру  гој фа  зи вр  ше  но је кли  нич  ко пра  ће-
њ е   е ф е  к а  т а   л е  ч е  њ а .
Ре зул та ти Сту ди ја је об у хва ти ла 184 же не про сеч не ста ро-
сти 66,2±9,4 го ди не. Код 40,2% ис пи та ни ца обо ље ње се кли-
нич ки  ис по љи ло  у  прет ход них  пет  го ди на.  Про сеч на  вред-
ност t-ско ра би ла је -3,1±0,84 код 160 ис пи та ни ца код ко јих је 
по ста вље на ди јаг но за осте о по ро зе (87%). Пре лом пр шљен-
с к о г   т е  л а   у о ч е н   ј е   к о д   24 %   и с  п и  т а  н и  ц а ,   с п о н  т а  н и   н е  в е р  т е -
б р а л  н и   п р е  л о  м и   д и  ј а г  н о  с т и  к о  в а  н и   с у   к о д   49, 4 %   ж е  н а ,   д о к  
с у  о б а  т и  п а  п р е  л о  м а  у т в р ђ е  н а  к о д  4 ,9 %  и с  п и  т а  н и  ц а .  О с т е  о -
по ро тич ни  пре ло ми  би ли  су  мно го  че шћи  код  же на  са  три 
и л и  ч е  т и  р и  ф а к  т о  р а  р и  з и  к а  ( p=0,001). Од 39 не же ље них деј-
с т а  в а  к о  ј а  с у  с е  ј а  в и  л а  т о  к о м  л е  ч е  њ а  б и  ф о с ф о  н а  т а ,  с а  м о  д в а  
(3,3%) озна че на су као те шка не же ље на деј ства. То ком ле че-
ња спон та ни пре ло ми су се ја ви ли код 13 ис пи та ни ца (7,1%).
За кљу чак Л е  ч е  њ е  ј е д  н о  м е  се ч  н о м  д о з о м  и б а н  д р о  н а  т а  т о  к о м  
ш е с т   м е  с е  ц и   п о  к а  з а  л о   с е   в е  о  м а   с и  г у р  н и м   и   б е з   т е  ж и х   н е -
же ље них деј ста ва ле ка, а бо ле сни це су га до бро под но си ле.
Кључ не  ре чи:  о с т е  о  п о  р о  з а ;   б и  ф о с  ф о  н а  т и ;   п р е  л о  м и ;   п р е -
в е н  ц и  ј а ;   л е  ч е  њ е
Проспективно клиничко испитивање примене једномесечне дозе 
ибандроната у лечењу остеопорозе и превенцији прелома код жена 
у постменопаузи – студија ORPHEUM
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